This study investigated the anti-infliximab-antibody response in pediatric patients receiving infliximab for juvenile idiopathic arthritis and other pediatric rheumatic diseases, with a focus on an analysis of the binding sites of these antibodies. We show that anti-infliximab antibodies developed in 43% of patients receiving infliximab therapy. Neutralization studies showed that in all these patients, the antibodies were directed toward the variable domains of infliximab, as they inhibited binding of infliximab to TNF.
COBISS.SI-ID: 28392409
Serum from 109 patients with primary APS, APS associated with autoimmune diseases, and patients with autoimmune diseases other than APS from five EU rheumatology centres were tested for anti-beta2-GPI antibodies. High, low and heterogeneous avidity IgG anti-beta2-GPI was found in 32/109, 17/109 and 60/109 patients respectively. Significantly more patients with APS were in the high avidity than in the low avidity anti-beta2-GPI group, while the opposite was observed for non-APS. High avidity anti-beta2-GPI was associated with thrombosis and APS, while in the low avidity anti-beta2-GPI group non-APS (predominantly SLE) patients prevailed.
COBISS.SI-ID: 28788185
Hypomorphic mutations in genes associated with severe combined immunodeficiency (SCID) or Omenn syndrome can also cause milder immunodeficiencies. We report 10 new patients with such "atypical" SCID and summarize 63 patients from the literature. This overview characterizes "atypical" SCID as a distinct disease with immune dysregulation in addition to infection susceptibility. Lymphopenia, reduced naive T cells and elevated IgE are suggestive, but not consistent features of the disease.
COBISS.SI-ID: 28966873